

8M2026 BUSINESS UPDATES

Imexpharm Corporation



August Performance

Positive August results driven by growth across both OTC & ETC channels

Gross revenue and net revenue grew by 12% and 8% y-o-y, respectively, thanks to significantly growth across both channels: (i) OTC revenue grew 2% y-o-y, driven by pharmacy chains and wholesale; (ii) ETC revenue surged 22% y-o-y, reflecting a positive demand for IMP's EU-GMP products.

Profit before tax (PBT) grew 4% m-o-m and 19% y-o-y.



8-Month Performance

Continued profit growth sustained by cost-saving initiatives

Gross revenue and net revenue reached VND 1,718 billion and VND 1,453 billion, down 7% and 8% y-o-y, respectively.

PBT and EBITDA continued to maintain growth momentum, increasing by 7% and 1% y-o-y, respectively, underpinned by manufacturing optimization initiatives aimed at reducing operating costs and enhancing production efficiency, particularly for EU-GMP injectable lines.

BUSINESS HIGHLIGHTS

01 SUSTAINABLE DEVELOPMENT

Imexpharm Honored in Top 50 Leading ESG Enterprises in Vietnam 2026

(Forbes Vietnam)



02 HAI PHONG BRANCH GRAND OPENING

